News

Study identifies changing trends in PBC incidence, mortality


 

FROM SCIENTIFIC REPORTS

References

A new study has identified a higher mortality rate among males with primary biliary cholangitis (PBC) and a lower sex ratio in disease prevalence than previously thought, according to findings published online in the journal Scientific Reports.

Investigators analyzed inpatient data from 2000 to 2009 for PBC patients in Denmark and in the Italian province of Lombardia. In the Lombardia cohort, 2,970 PBC patients were identified, with a female to male ratio of 2.3:1. In the Denmark population, 722 cases were identified, with a female to male ratio of 4.2:1, reported Dr. Ana Lleo from the Humanitas Clinical and Research Center in Rozzano, Italy, and her coauthors.

©Tashatuvango/Thinkstock

Among the Lombardia patients, survival at 1, 5, and 10 years was significantly higher for females (89%, 95% confidence interval, 88%-91%; 77%, 95% CI, 75%-78%; and 67%, 95% CI, 65%-70%, respectively) than for males (78%, 95% CI, 75%-80%; 55%, 95% CI, 52%-59%; and 47%, 95% CI, 43%-51%, respectively). Findings were similar in the Denmark cohort, with female patients having higher survival rates (survival at 1, 5, and 10 years of 90%, 87%-92%; 73%, 95% CI, 69%-77%; and 60%, 95% CI, 53%-67%, respectively) than males (72%, 95% CI, 63%-79%; 42%, 95% CI, 32%-51%; and 27%, 95% CI, 14%-43%, respectively), the authors reported.

The study findings question long-held beliefs on PBC, the authors said. Hepatologists should be aware that “male PBC patients have higher mortality than [do] their female counterparts, such that close clinical follow-up and checking adherence to therapy are strongly recommended,” Dr. Lleu and colleagues concluded.

Read the full article in Scientific Reports: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872151.

mrajaraman@frontlinemedcom.com

Recommended Reading

HCV regimen found safe, effective in patients with severe renal disease
MDedge Internal Medicine
Initiative dramatically raises HCV screening, treatment
MDedge Internal Medicine
Chronic HCV boosts hospitalization risk, not just for liver
MDedge Internal Medicine
Ocaliva approved for primary biliary cholangitis
MDedge Internal Medicine
HIV/HCV coinfection further raises inflammatory markers
MDedge Internal Medicine
Dually active antiretrovirals protect HIV patients against HBV infection
MDedge Internal Medicine
Tenofovir may prevent mother-to-child transmission of hepatitis B
MDedge Internal Medicine
Pioglitazone safe and effective for steatohepatitis in T2DM
MDedge Internal Medicine
HCV patients had distinct mucosal microbiome
MDedge Internal Medicine
New HCV test approach could cut costs, streamline diagnosis
MDedge Internal Medicine